CJC-1295 DAC vs no-DAC: half-life, dosing, and use

Last updated 2026-07-26

What is the actual difference between CJC-1295 DAC and no-DAC?

The difference comes down to one chemical addition and what it does to the molecule's lifespan in blood. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), built from the first 29 amino acids of native GHRH with four substitutions that resist enzymatic breakdown ^[1]. That modified backbone is the same in both versions. The "DAC" version adds Drug Affinity Complex, a maleimide-linked chemical handle that covalently attaches to circulating albumin once injected. Albumin has a serum half-life measured in weeks, and by riding along with it, CJC-1295 with DAC gains a half-life of about 6 to 8 days in humans, per the pharmacokinetic data reported in the compound's original Phase 1/2 trial ^[2]. CJC-1295 without DAC is just the modified GHRH(1-29) peptide on its own, sometimes labeled "Mod GRF 1-29" in gray-market catalogs. Without the albumin anchor, it behaves like a normal peptide hormone: absorbed, active for a short window, then cleared. Its functional half-life in the body is around 30 minutes or less, similar to native GHRH's few-minute half-life ^[3]. So the "vs" in this comparison isn't really about a different drug target. Both stimulate the same GHRH receptor on pituitary somatotrophs. The comparison is entirely about duration of action and what that means for dosing pattern, GH pulse shape, and practical injection burden. For a fuller mechanism walkthrough, see cjc 1295.

CJC-1295 DAC vs no-DAC: side-by-side comparison

Why does the DAC half-life matter for dosing?

A 6 to 8 day half-life changes the entire dosing logic. In the original Phase 2 trial, a single subcutaneous dose of CJC-1295 with DAC produced elevated GH levels sustained over roughly 6 to 9 days, with IGF-1 levels staying above baseline for about 9 to 11 days after a single injection ^[2]. Repeated weekly dosing in that trial maintained mean IGF-1 elevations of 1.5 to 3 times baseline over a multi-week period ^[2]. That's the pharmacokinetic case for once-weekly or twice-weekly injection schedules that show up in dosing guides. Because the drug accumulates and clears slowly, spacing doses out doesn't mean gaps in GH stimulation the way it would with a short-acting peptide. No-DAC CJC-1295 doesn't have that buffer. Its GH-releasing action is close to native GHRH's pulse-and-clear pattern, which is why protocols pairing it with a secretagogue tend to use multiple daily injections, often timed around sleep and training, to approximate the body's own GHRH pulsing rather than one sustained elevation. For a breakdown of actual dosing numbers and schedules people use for the DAC version specifically, see cjc 1295 with dac and the general cjc 1295 dosage guide.

Does DAC's longer action mean a stronger or better GH response?

Not necessarily stronger, just different in shape. Longer duration of receptor stimulation is not the same as a bigger GH pulse. In fact, one of the open questions researchers raised with continuous or long-acting GHRH analogues is whether sustained, non-pulsatile GH elevation could down-regulate GHRH receptor sensitivity over time, since natural GH secretion is pulsatile by design and continuous exposure to secretagogues has been shown in some GH receptor and somatostatin research to blunt responsiveness ^[4]. The honest answer is that nobody has run a head-to-head trial comparing DAC and no-DAC CJC-1295 for body composition, strength, or long-term IGF-1 stability outcomes. The 2006 trial data is about pharmacokinetics and short-term GH/IGF-1 levels, not about downstream physical outcomes like lean mass or fat loss ^[2]. Everything past that point, in either direction, is forum extrapolation rather than published data. If a source tells you DAC is definitively "better" or "worse" for muscle gain, that's opinion dressed as fact.

How does the injection schedule actually differ in practice?

This is where the DAC vs no-DAC choice has real, practical weight, independent of any physiological argument. CJC-1295 with DAC, based on its measured half-life, is used in research and off-label contexts on a schedule of roughly once or twice weekly. Fewer injections is the entire point of the DAC modification; that was the design goal stated in the original patent and trial work on long-acting GHRH analogues ^[2]. CJC-1295 no-DAC needs to be injected far more often, commonly once to three times a day in the protocols people describe, usually timed around waking GH pulses (morning, pre-workout, before bed) to mimic natural GHRH rhythm. That's a meaningfully higher injection burden: 7 to 21 injections a week for no-DAC versus 1 to 2 for DAC, using the same rough weekly total peptide exposure as a comparison point. That difference alone drives most people's practical decision. It has nothing to do with which one is "more effective" and everything to do with tolerance for needles and reconstitution logistics.

Which one is usually paired with ipamorelin, and why?

Both versions are commonly paired with ipamorelin, a selective ghrelin-receptor agonist (a GH secretagogue in the same functional family as GHRP-6 and hexarelin, but without meaningfully stimulating cortisol or prolactin in the studies that have characterized it) ^[5]. The rationale is mechanistic complementarity: GHRH analogues like CJC-1295 increase the amount of GH released per pulse, while ghrelin-receptor agonists like ipamorelin increase pulse frequency and amplify the release event itself. Combining a GHRH-receptor agonist with a ghrelin-receptor agonist has been shown in earlier GHRP/GHRH combination research to produce a larger GH pulse than either compound alone, because the two act on separate receptor pathways that converge on GH release ^[6]. That additive mechanism is real pharmacology, documented in older combination studies using other GHRH and GHRP pairs, not something invented on forums. What is not settled is which specific pairing schedule (DAC weekly plus daily ipamorelin, versus no-DAC multiple-times-daily plus ipamorelin) produces a superior outcome in humans over months of use. No controlled trial has directly tested the CJC-1295/ipamorelin combination specifically for body composition or performance endpoints. The combination is popular because the mechanism is plausible, not because there's a published trial validating the stack itself.

What does the actual clinical trial evidence show, and what is bodybuilding lore?

It helps to separate the two piles cleanly. What's documented: CJC-1295 with DAC's pharmacokinetics (half-life, GH and IGF-1 elevation curves after single and repeat dosing) come from a real Phase 1/2 dose-escalation and multi-dose trial published by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006 ^[2]. That paper is the single most-cited primary source for this compound, and it's worth reading the actual conclusion: the study reported that CJC-1295 "increased plasma GH and IGF-I levels in a dose-dependent manner" and that repeated dosing sustained those elevations over the dosing interval ^[2]. What's folklore: claims about specific fat-loss percentages, sleep quality improvements, joint healing, or anti-aging effects attributed to CJC-1295 (with or without DAC) circulating on bodybuilding forums are not backed by the cited trial or any other controlled human study of this compound. Neither is CJC-1295, in either form, approved by the FDA for any indication; it exists in a regulatory gray zone as a research chemical, and the FDA has specifically flagged compounded GHRH-analogue peptides for safety and quality concerns in its guidance on bulk drug substances . Read cjc 1295 side effects before assuming either version is risk-free.

Which one is more commonly sold, and does DAC cost more?

Both forms are available from gray-market research chemical suppliers, and pricing varies by vendor, purity claims, and vial size rather than by any regulated benchmark, since neither is a controlled pharmaceutical product with a listed price. As a rough pattern across supplier catalogs, CJC-1295 with DAC tends to run somewhat higher per milligram than no-DAC, likely reflecting the added synthesis step for the DAC conjugation chemistry, though there's no standardized pricing data to cite here beyond noting that per-mg costs and purity testing vary widely between suppliers. Because this market is unregulated, the biggest cost risk isn't the price tag, it's what's actually in the vial. Third-party mass spec or HPLC testing, when a supplier provides it, matters more than the sticker price. See cjc 1295 for sale for what to check before buying either version.

Which one should you actually choose?

If the goal is fewer injections and a documented, sustained GH/IGF-1 elevation profile backed by real pharmacokinetic data, CJC-1295 with DAC is the version with an actual human trial behind its half-life and dosing pattern ^[2]. That's a meaningful practical edge: 1 to 2 injections weekly instead of daily. If the goal is closer mimicry of natural pulsatile GHRH release, and you're comfortable with more frequent injections, no-DAC is the theoretically "cleaner" mechanism, though there isn't a controlled trial proving that pulsatile dosing beats sustained dosing for any real-world outcome in this specific compound. Neither choice is FDA-approved, and neither has trial data on long-term outcomes like body composition, strength, or safety beyond a matter of weeks. If you're weighing this decision, start with the pharmacokinetics guide at cjc 1295 with dac, then check actual dosing math at the cjc-1295 dac dosage calculator before doing anything with a vial. Where people want a provider-reviewed source rather than an anonymous vendor, CJC-1295 Co reviews sourcing routes and points to a fulfilling pharmacy partner rather than compounding or selling anything directly.

What are the known side effects and safety differences between the two?

Reported side effects overlap heavily between the two forms, since both act on the same GHRH receptor pathway. In the Teichman 2006 trial, the most commonly reported adverse events with CJC-1295 with DAC were injection site reactions (pain, erythema) and transient flushing, with no serious adverse events reported at the doses tested ^[2]. GH-axis stimulation in general carries theoretical risks of increased insulin resistance, fluid retention, and joint discomfort, patterns seen with other GH secretagogues and with recombinant GH itself, though the trial itself didn't report these as significant findings at studied doses. A specific concern raised for DAC specifically: because it stays in circulation for days and continuously stimulates GH release, a small number of practitioners and researchers have voiced concern about the theoretical risk of sustained supraphysiologic GH/IGF-1 exposure compared to the more pulsed profile of no-DAC or endogenous GHRH, though no long-term trial has quantified that risk directly for this compound. No-DAC's shorter action means any adverse reaction clears faster, which some people treat as a safety buffer, though this hasn't been tested head-to-head either. Full detail is in cjc 1295 side effects.

Frequently asked questions

Is CJC-1295 with DAC stronger than no-DAC?

Not in terms of a bigger GH pulse per dose. DAC's advantage is duration of action (roughly 6-8 days versus about 30 minutes) ^[2][3], not amplitude. No trial has shown DAC produces a larger GH response per injection; it produces a longer-sustained one.

How often do you inject CJC-1295 no-DAC versus DAC?

Based on documented half-life data, DAC is used roughly once or twice weekly, while no-DAC's short half-life (about 30 minutes) means it's typically dosed multiple times a day in described protocols, often around waking hours or training ^[2][3].

Does CJC-1295 DAC or no-DAC work better with ipamorelin?

Both are paired with ipamorelin, since ipamorelin works through a separate ghrelin-receptor pathway and combining GHRH and ghrelin-receptor agonists has shown additive GH release in earlier combination studies ^[6]. No trial has compared which CJC-1295 form pairs better with ipamorelin specifically.

Is CJC-1295 FDA approved in either form?

No. Neither CJC-1295 with DAC nor without DAC is FDA-approved for any use. It's sold as a research chemical, and the FDA has raised broader concerns about compounded GHRH-analogue peptides in its bulk drug substance guidance ^[7].

What does DAC actually stand for and do chemically?

DAC stands for Drug Affinity Complex, a maleimide group that covalently binds circulating albumin after injection. Because albumin has a long serum half-life, the attached peptide is protected from rapid clearance, extending CJC-1295's half-life from minutes to roughly 6-8 days ^[1][2].

Which lasts longer in the body, CJC-1295 with DAC or without?

CJC-1295 with DAC lasts far longer, with a reported half-life of approximately 6 to 8 days versus roughly 30 minutes or less for the no-DAC version, according to the pharmacokinetic data in the original human trial ^[2][3].

Can you use CJC-1295 no-DAC and DAC together?

There's no published trial testing this combination, and doing so would layer two different GH-release durations without clear rationale or safety data. Most protocols described in dosing guides use one form or the other, not both simultaneously.

Does CJC-1295 raise IGF-1 levels?

Yes. In the 2006 Phase 2 trial, CJC-1295 with DAC raised IGF-1 levels 1.5 to 3 times above baseline, sustained across the weekly dosing interval, and single doses kept IGF-1 elevated for roughly 9 to 11 days ^[2].

What are the main side effects reported with CJC-1295?

The 2006 trial reported injection site reactions and transient flushing as the most common adverse events, with no serious adverse events at studied doses ^[2]. Broader GH-axis concerns like fluid retention and insulin sensitivity changes are theoretical extrapolations from GH pharmacology generally, not findings specific to this trial.

Is no-DAC CJC-1295 the same as Mod GRF 1-29?

Yes, in gray-market naming, "Mod GRF 1-29" and "CJC-1295 without DAC" refer to the same modified GHRH(1-29) peptide lacking the Drug Affinity Complex, distinguishing it from the long-acting DAC-conjugated version.

How much does CJC-1295 with DAC cost compared to no-DAC?

Pricing varies widely by supplier and isn't standardized since neither form is a regulated pharmaceutical product. As a general pattern, DAC tends to cost more per milligram, likely reflecting the added conjugation step, but purity and testing quality matter more than price when evaluating sources.

Which is safer, CJC-1295 with DAC or without DAC?

No controlled trial has directly compared long-term safety between the two forms. No-DAC clears within about 30 minutes, so any adverse reaction resolves quickly. DAC's multi-day half-life means sustained exposure, which some clinicians view as a theoretical caution, though this hasn't been formally studied ^[2][3].

Sources

1. PubChem, CJC-1295 compound summary: CJC-1295 is a modified GHRH(1-29) analogue with amino acid substitutions for enzymatic resistance
2. Teichman et al., J Clin Endocrinol Metab, 2006: CJC-1295 with DAC half-life of ~6-8 days, sustained GH/IGF-1 elevation, and dose-dependent response
3. PubMed, GHRH pharmacokinetics review: Native GHRH and unmodified short-acting analogues have half-lives on the order of minutes
4. NIH, StatPearls: Growth Hormone Physiology: GH secretion is naturally pulsatile and receptor sensitivity is influenced by exposure pattern
5. PubMed, Ipamorelin receptor selectivity study: Ipamorelin is a selective ghrelin-receptor agonist without significant cortisol or prolactin stimulation
6. PubMed, GHRH and GHRP combination study: Combining GHRH-receptor agonists with GHRP/ghrelin-receptor agonists produces additive GH release via separate pathways